Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Press release, Helsinki, 22 March 2017 at 3 pm
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that its wholly owned subsidiary Nexstim Inc. has signed a new Independent Selling Representative Agreement in the U.S. with JTec Surgical, Inc. to represent the Nexstim Brain Mapping (NBS) system. The NBS system is used for the pre-surgical mapping of the speech and motor cortices of the brain.
JTec Surgical will cover the Southern California region, where it has established a strong presence and relationships in the neurosurgical technology space for more than 25 years. The JTec portfolio includes a number of carefully selected and innovative products for neurosurgical procedures.
Commenting on the event, John Liedtky, General Manager U.S. stated: "The Nexstim commercial strategy continues to progress well, as I am very pleased that we have added JTec Surgical, Inc to the team of U.S. Independent Selling Representatives for the Nexstim NBS Brain Mapping technology. We look forward to collaborating with our new Southern Californian partner to drive further market adoption of this impactful and valuable technology"
NEXSTIM PLC
Martin Jamieson, Chairman and CEO
Further information is available on the website www.nexstim.com or by telephone:
Nexstim +447715163942
Martin Jamieson, Chairman and CEO [email protected]
Citigate Dewe Rogerson +44 (0)207 2821066
Katja Stout [email protected]
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f238a268-3627-4efb-8195-aa14c7a01669
